These data demonstrate that the catalytic activity of LSD1 is not required for the clonogenic potential of human THP1 or murine MLL-AF9 AML cells and further indicate that tranylcypromine-derivative pharmacologic inhibitors target histone demethylation-independent activities of LSD1. The gene discussed is KMT2A; the disease is acute myeloid leukemia.